201 related articles for article (PubMed ID: 30257426)
1. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
[TBL] [Abstract][Full Text] [Related]
2. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
3. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowacka M; Kaźmierczak D; Andrzejewska M; Rusek D; Brązert M; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583585
[TBL] [Abstract][Full Text] [Related]
4. Effect of
Nowacka M; Ginter-Matuszewska B; Świerczewska M; Sterzyńska K; Nowicki M; Januchowski R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328460
[TBL] [Abstract][Full Text] [Related]
5. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
6. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
7. PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
Świerczewska M; Sterzyńska K; Wojtowicz K; Kaźmierczak D; Iżycki D; Nowicki M; Zabel M; Januchowski R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027318
[No Abstract] [Full Text] [Related]
8. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
Klejewski A; Świerczewska M; Zaorska K; Brązert M; Nowicki M; Zabel M; Januchowski R
Anticancer Res; 2017 Apr; 37(4):1625-1636. PubMed ID: 28373423
[TBL] [Abstract][Full Text] [Related]
9. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
[TBL] [Abstract][Full Text] [Related]
10. The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines.
Wojtowicz K; Świerczewska M; Nowicki M; Januchowski R
Adv Med Sci; 2023 Sep; 68(2):379-385. PubMed ID: 37806183
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
[TBL] [Abstract][Full Text] [Related]
13. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.
Tumbarello DA; Temple J; Brenton JD
Mol Cancer; 2012 May; 11():36. PubMed ID: 22640878
[TBL] [Abstract][Full Text] [Related]
14. The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines.
Borucka J; Sterzyńska K; Kaźmierczak D; Świerczewska M; Nowacka M; Wojtowicz K; Klejewski A; Nowicki M; Zabel M; Ramlau R; Januchowski R
Biomed Pharmacother; 2022 Jun; 150():113036. PubMed ID: 35489285
[TBL] [Abstract][Full Text] [Related]
15. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
16. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.
Januchowski R; Zawierucha P; Ruciński M; Nowicki M; Zabel M
Biomed Res Int; 2014; 2014():365867. PubMed ID: 24804215
[TBL] [Abstract][Full Text] [Related]
18. Piperine Targets Different Drug Resistance Mechanisms in Human Ovarian Cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs.
Wojtowicz K; Sterzyńska K; Świerczewska M; Nowicki M; Zabel M; Januchowski R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921897
[TBL] [Abstract][Full Text] [Related]
19. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.
Mo QQ; Chen PB; Jin X; Chen Q; Tang L; Wang BB; Li KZ; Wu P; Fang Y; Wang SX; Zhou JF; Ma D; Chen G
Acta Pharmacol Sin; 2013 Apr; 34(4):541-8. PubMed ID: 23474708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]